CDKN2A and metastatic melanoma: The YUMM1.1 parental melanoma cell line carries the genetic alterations of BRAFV600E mutation and deletion of phosphatase and tensin homolog (PTEN) and cyclin-dependent kinase inhibitor 2 (CDKN2A) and thus recapitulates the genetic profile of human metastatic melanoma [33].